Iterum Therapeutics Reports Third Quarter 2023 Financial Results
14 nov. 2023 07h00 HE
|
Iterum Therapeutics PLC
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 08h30 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
24 oct. 2023 08h00 HE
|
Iterum Therapeutics PLC
– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics to Present Data at IDWeek 2023
12 oct. 2023 09h15 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
11 août 2023 07h00 HE
|
Iterum Therapeutics PLC
--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
04 août 2023 17h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data at ASM Microbe 2023
12 juin 2023 18h23 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2023 Financial Results
12 mai 2023 07h00 HE
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum),...
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
20 avr. 2023 17h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
16 mars 2023 07h00 HE
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE...